Premenstrual syndrome.
Goldfien
A
A
Harvard Medical School, Boston, Massachusetts.
D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D002118:Calcium / Q000627:therapeutic use; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D004042:Dietary Fats, Unsaturated / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D005228:Fatty Acids, Essential / Q000627:therapeutic use; D005260:Female; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D008041:Linoleic Acids; D008903:Minerals / Q000627:therapeutic use; D031665:Oenothera biennis; D010938:Plant Oils; D011293:Premenstrual Syndrome / Q000209:etiology / Q000503:physiopathology* / Q000628:therapy*; D011613:Psychotherapy; D014815:Vitamins / Q000627:therapeutic use; D017965:gamma-Linolenic Acid
D014151:Anti-Anxiety Agents; D016861:Cyclooxygenase Inhibitors; D004042:Dietary Fats, Unsaturated; D004232:Diuretics; D005228:Fatty Acids, Essential; D006728:Hormones; D008041:Linoleic Acids; D008903:Minerals; D010938:Plant Oils; D014815:Vitamins; C028498:evening primrose oil; D017965:gamma-Linolenic Acid; D002118:Calcium